Achieved 123% year-over-year revenue growth in 2025, driven by ZORYVE becoming the #1 branded nonsteroidal topical across psoriasis, seborrheic dermatitis, and atopic dermatitis. Attributed commercial success to the 'steroid-sparing' movement, where providers and patients are actively seeking safe, long-term alternatives to topical corticosteroids. Maintained a stable gross-to-net in the 50s throughout 2025, validating a pricing strategy designed to balance broad payer access with sustainable investor ...